Evidence map›Paper›PMID 41460405›Full record

ArticleEndocrine2025

Effect of Goserelin acetate on non-invasive indices of hepatic steatosis in women with endometriosis.

Dimitrios A Anastasilakis, Athanasios D Anastasilakis, Athina Gkiomisi, Anastasios Semertzidis, Panagiotis Nikolakopoulos, Stergios Papachatzopoulos, Angelos Daniilidis, Dimitrios G Goulis, Antonis Goulas, Stergios A Polyzos

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dimitrios A AnastasilakisFirst Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. dimitanast@auth.gr.ORCID 0000-0001-8621-7478
Athanasios D AnastasilakisDepartment of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece.
Athina GkiomisiDepartment of Obstetrics and Gynaecology, 424 General Military Hospital, Thessaloniki, Greece.
Anastasios SemertzidisFirst Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Panagiotis NikolakopoulosDepartment of Obstetrics and Gynaecology, 424 General Military Hospital, Thessaloniki, Greece.
Stergios PapachatzopoulosDepartment of Obstetrics and Gynaecology, 424 General Military Hospital, Thessaloniki, Greece.
Angelos DaniilidisFirst Department of Obstetrics and Gynaecology, School of Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Dimitrios G GoulisUnit of Reproductive Endocrinology, First Department of Obstetrics and Gynaecology, School of Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Antonis GoulasFirst Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Stergios A PolyzosFirst Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMenopause has been associated with metabolic dysfunction-associated steatotic liver disease (MASLD). This study primarily aimed to evaluate changes in non-invasive indices of hepatic steatosis in premenopausal women with endometriosis after treatment with goserelin, resulting in pharmacologic menopause.

methodsThis was a post-hoc study of an interventional study. Non-invasive indices of hepatic steatosis and, secondarily, fibrosis were calculated in premenopausal women with endometriosis (intervention group, n = 21) before (baseline), 6 months after goserelin treatment (estrogen-deficient period), and 6 months after goserelin discontinuation (estrogen replenishment period). Matched premenopausal women were recruited for baseline comparisons (control group, n = 27). Steatosis was evaluated using the Hepatic Steatosis Index (HSI), Triglyceride/Glucose Index (TyG), TyG-Body Mass Index (BMI), Triglyceride/High Density Lipoprotein (TG/HDL), Metabolic Score for Insulin Resistance (MetS-IR), Dallas Steatosis Index (DSI), and Framingham Steatosis Index (FSI), and fibrosis with BMI – Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) Ratio Diabetes Mellitus (BARD).

resultsThe non-invasive indices of hepatic steatosis and BARD were similar between patients and controls at baseline and did not significantly change after goserelin treatment, except for MetS-IR, which showed an overall significant change (p = 0.04); however, in pairwise comparisons after Bonferroni correction, no significant difference in MetS-IR was observed between baseline (34.8 ± 7.7), 6 months (33.3 ± 9.0), and endpoint (35.0 ± 8.1) values. As expected, the lipid profiles and insulin resistance worsened during the study.

conclusionNon-invasive hepatic steatosis and BARD indices were not significantly affected by estrogen deficiency caused by 6-month goserelin treatment in premenopausal women with endometriosis.

Indexed as

EndometriosisFatty LiverGoserelinAdultAlanine TransaminaseAspartate AminotransferasesFemaleHumansInsulin ResistanceMiddle AgedPremenopauseTriglyceridesAlanine TransaminaseAspartate AminotransferasesGoserelinTriglyceridesFibrosisGoserelinMenopauseMetabolic dysfunction-associated steatohepatitisMetabolic dysfunction-associated steatotic liver diseaseNonalcoholic fatty liver diseaseNon-invasive indicesSteatosis

Identifiers

PMID41460405

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.